Mainz BioMed N.V. | Finanzwire

Basculer en Français

8461	Companies
126373	Keywords
64269	Articles
67737	Press releases

Home
Companies
Mainz BioMed N.V.

BRIEF

published on 01/21/2025 at 14:06, 1 day 2 hours ago

Mainz Biomed Launches U.S. Study for Advanced Adenoma Detection

Clinical Study Mainz Biomed Colorectal Cancer Biomarkers EAArly DETECT 2
PRESS RELEASE

published on 01/21/2025 at 14:01, 1 day 2 hours ago

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
Mainz Biomed initiates U.S. clinical study to evaluate next-generation CRC test on advanced adenomas over large patient population. Study targets topline results by Q4 2025, focusing on biomarkers and AI algorithm

Clinical Study Mainz Biomed CRC Screening Next Generation Test Advanced Adenomas
BRIEF

published on 12/19/2024 at 14:05, 1 month 3 days ago

Mainz Biomed Partners with Quest Diagnostics for Cancer Screening Trial

FDA Approval Clinical Trials Colorectal Cancer Diagnostic Services Healthcare Partnership
PRESS RELEASE

published on 12/19/2024 at 14:00, 1 month 3 days ago

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Mainz Biomed forms agreement with Quest Diagnostics to provide clinical trials lab services for colorectal cancer screening test, enhancing early cancer detection efforts

Clinical Trials Early Detection Mainz Biomed Colorectal Cancer Screening Quest Diagnostics
BRIEF

published on 11/29/2024 at 14:50, 1 month 23 days ago

Mainz Biomed Announces Reverse Stock Split to Enhance Nasdaq Compliance

Reverse Stock Split Shareholder Approval Nasdaq Compliance Market Price Mainz Biomed
PRESS RELEASE

published on 11/29/2024 at 14:45, 1 month 23 days ago

Mainz Biomed Announces Stock Split
Mainz Biomed N.V. announces a 1-for-40 reverse stock split to comply with Nasdaq listing standards and increase investor appeal. Effective from December 3, 2024

Investors Nasdaq Mainz Biomed Molecular Genetics Stock Split
BRIEF

published on 11/12/2024 at 15:05, 2 months 10 days ago

Mainz Biomed Collaborates with Thermo Fisher for Cancer Screening Development

Cancer Screening Mainz Biomed Colorectal Detection Thermo Fisher Partnership Biotech Collaboration
PRESS RELEASE

published on 11/12/2024 at 15:00, 2 months 10 days ago

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
Mainz Biomed and Thermo Fisher Scientific sign a collaboration agreement for the development of next generation colorectal cancer screening product for global markets

Global Markets Thermo Fisher Scientific Mainz Biomed Collaboration Agreement Colorectal Cancer Screening
BRIEF

published on 10/21/2024 at 14:06, 3 months 1 day ago

Mainz BioMed Releases Mid-Year 2024 Financial Results

Financial Results FDA Feedback Mainz Biomed ColoAlert® Cancer Detection
PRESS RELEASE

published on 10/21/2024 at 14:01, 3 months 1 day ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed reports 4% revenue increase in Mid-Year 2024 Financial Results with 32% decrease in loss from operations. Company highlights successful studies at ASCO and outlines strategic plan for 2025

Financial Results Corporate Update ColoAlert Mainz Biomed EAArly DETECT

1 2 ... 9

Accesswire

Published on 01/22/2025 at 16:15, 19 minutes ago

Electric Motor Design Firm ECM Appoints David Hartwell as Chief Sales Officer
Published on 01/22/2025 at 15:00, 1 hour 34 minutes ago

New Financial App Helps People Develop A Healthier Relationship With Their Money
Published on 01/22/2025 at 15:00, 1 hour 34 minutes ago

Preservica Academy Launches to Help Information Professionals Accelerate Skills in Active Digital Preservation
Published on 01/22/2025 at 15:00, 1 hour 34 minutes ago

Rings With a Story: Ma Folie’s Unique Approach to Custom Jewellery
Published on 01/22/2025 at 15:00, 1 hour 34 minutes ago

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

View all ACCESSWIRE

EQS Group

Published on 01/22/2025 at 16:00, 34 minutes ago

Five Key Trends in Artificial Intelligence that will revolutionize agriculture in 2025
Published on 01/22/2025 at 16:00, 34 minutes ago

Director/PDMR Shareholding
Published on 01/22/2025 at 14:40, 1 hour 53 minutes ago

LION E-Mobility AG: Partial conversion of convertible loan by major shareholder
Published on 01/22/2025 at 14:37, 1 hour 56 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 01/22/2025 at 14:36, 1 hour 58 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc

Les Echos

Published on 01/22/2025 at 07:04, 9 hours 30 minutes ago

Gimv launches strategy to accelerate its growth
Published on 01/21/2025 at 18:12, 22 hours 22 minutes ago

Half yearly report on the liquidity contract
Published on 01/21/2025 at 08:30, 1 day 8 hours ago

Cie du Bois Sauvage: Buy back of own shares – week from 13/01/2025 to 17/01/2025
Published on 01/21/2025 at 07:00, 1 day 9 hours ago

Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China
Published on 01/20/2025 at 18:49, 1 day 21 hours ago

Reporting on share buyback transactions carried out between January 13 and January 16, 2025

View all LES ECHOS COMFI WIRE